A Firm's Mission to Contribute to Cancer Research

A Firm's Mission to Contribute to Cancer Research

Healthcare Tech Outlook | Wednesday, November 10, 2021

Predictive Oncology is using artificial intelligence (AI) to speed up drug development, enhance clinical trial outcomes, and pave the way for a new era of cancer research.

FREMONT, CA: “Eliminating cancer may seem like a lofty goal, and indeed such a complex disease is not going to be cured overnight. But, with modern technology and the power of AI, we have at our disposal some of the most potent tools to solve the challenges facing us in cancer research. Now that we can contextualize and cross-reference hundreds of thousands of case studies against detailed information about each and every tumor we have received, we can ensure our treatments are tailor-made to be most effective for each and every patient,” states Melville Engle, CEO and Chairman of the Board of Predictive Oncology.

Predictive Oncology, an oncology and cancer research firm that uses big data and machine learning to better pharmaceutical development and forecast treatment outcomes, has rolled out a new website emphasizing its role in furthering its mission. Predictive Oncology and its subsidiaries, Helomics, Soluble Biotech, and TumorGenesis, are part of the larger goal of eradicating cancer by forecasting treatment outcomes and assisting in developing and optimizing cancer medications, according to the website.

Here is a closer look at each of Predictive Oncology’s divisions and how they contribute to cancer research and lifesaving:

Helomics: Helomics has a database with information on 137 different types of cancers, as well as more than 15 years of treatment outcome data spanning over 150,000 clinical cases. Helomics uses its own AI software, the Computational Research Engine (CoRE), to analyze this large amount of data and customize cancer treatments for patients. It can also aid in developing new targeted therapeutics in partnership with pharmaceutical companies, allowing for the faster identification of beneficial treatments and their progression to clinical trials.

Soluble Biotech: Soluble Biotech is a company that makes soluble and stable protein formulations, such as vaccines, antibodies, large and tiny proteins, and protein complexes. Soluble Biotech can assist reduce the cost, time, and resources required to optimize formulations, reducing the typical period from a year to only three months.

TumorGenesis: TumorGenesis allows researchers to understand better cancer cells detected in blood and organ cancers. TumorGenesis accomplishes this by growing cancer cells in the lab while preserving the specific DNA/RNA and proteomic signatures seen in a patient’s body. TumorGenesis provides a granular perspective of the tumor and the information needed to treat the patient’s cancer efficiently. TumorGenesis focuses on ovarian cancer tumors, with 25 ovarian cancer cell lines representing 90 percent of the covered ovarian malignancies.

Weekly Brief